Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

PFPaula Fernández‐CaldasABAna BenzaquénMBMariana Bastos‐Oreiro

Discussion

Loading...

Member takes

Overview

Observational analysis shows early CRS intervention increases risk of cytopenias and infections in large B-cell lymphoma patients, suggesting revised management strategies are needed.

Key Points

  • Higher incidence of cytopenias was linked to early intervention for cytokine release syndrome, emphasizing caution in patient management.
  • Among 589 patients, early CRS management had a lower rate of grade 2+ CRS (21% vs 53%), indicating potential benefit in terms of toxicity.
  • This multicenter study highlighted the significant association between cytopenias and increased infection rates following early CRS intervention.
  • The study suggests that while toxicity management may improve, efficacy remains unchanged, underscoring the need for targeted strategies.

Cite This Study

Fernández‐Caldas et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5a7https://doi.org/10.1182/blood-2025-1944
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations
  2. 2Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts2025 · 1 citations
  3. 3Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis2025
  4. 4BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  5. 5Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025